Schumacher Samuel G, Sohn Hojoon, Qin Zhi Zhen, Gore Genevieve, Davis J Lucian, Denkinger Claudia M, Pai Madhukar
McGill University Department of Epidemiology & Biostatistics, Montreal, Canada.
McGill International TB Centre, Montreal, Canada.
PLoS One. 2016 Mar 8;11(3):e0151073. doi: 10.1371/journal.pone.0151073. eCollection 2016.
Several reviews on the accuracy of Tuberculosis (TB) Nucleic Acid Amplification Tests (NAATs) have been performed but the evidence on their impact on patient-important outcomes has not been systematically reviewed. Given the recent increase in research evaluating such outcomes and the growing list of TB NAATs that will reach the market over the coming years, there is a need to bring together the existing evidence on impact, rather than accuracy. We aimed to assess the approaches that have been employed to measure the impact of TB NAATs on patient-important outcomes in adults with possible pulmonary TB and/or drug-resistant TB.
We first develop a conceptual framework to clarify through which mechanisms the improved technical performance of a novel TB test may lead to improved patient outcomes and outline which designs may be used to measure them. We then systematically review the literature on studies attempting to assess the impact of molecular TB diagnostics on such outcomes and provide a narrative synthesis of designs used, outcomes assessed and risk of bias across different study designs.
We found 25 eligible studies that assessed a wide range of outcomes and utilized a variety of experimental and observational study designs. Many potentially strong design options have never been used. We found that much of the available evidence on patient-important outcomes comes from a small number of settings with particular epidemiological and operational context and that confounding, time trends and incomplete outcome data receive insufficient attention.
A broader range of designs should be considered when designing studies to assess the impact of TB diagnostics on patient outcomes and more attention needs to be paid to the analysis as concerns about confounding and selection bias become relevant in addition to those on measurement that are of greatest concern in accuracy studies.
已有多项关于结核病(TB)核酸扩增检测(NAATs)准确性的综述,但关于其对患者重要结局影响的证据尚未得到系统综述。鉴于近期评估此类结局的研究有所增加,以及未来几年将上市的结核病NAATs种类不断增多,有必要汇总现有的关于影响而非准确性的证据。我们旨在评估用于衡量结核病NAATs对疑似肺结核和/或耐药结核病成人患者重要结局影响的方法。
我们首先构建一个概念框架,以阐明新型结核病检测技术性能的改善可能通过哪些机制导致患者结局改善,并概述可用于衡量这些机制的设计。然后,我们系统综述了试图评估分子结核病诊断对这些结局影响的研究文献,并对所使用的设计、评估的结局以及不同研究设计中的偏倚风险进行了叙述性综合分析。
我们发现了25项符合条件的研究,这些研究评估了广泛的结局,并采用了各种实验性和观察性研究设计。许多潜在强大的设计选项从未被使用过。我们发现,关于患者重要结局的现有证据大多来自少数具有特定流行病学和操作背景的环境,并且混杂因素、时间趋势和不完整的结局数据未得到充分关注。
在设计研究以评估结核病诊断对患者结局的影响时,应考虑更广泛的设计,并且需要更多地关注分析,因为除了准确性研究中最关注的测量问题外,混杂和选择偏倚问题也变得很重要。